Brokerages Set Natera, Inc. (NASDAQ:NTRA) PT at $152.67

Natera, Inc. (NASDAQ:NTRA) has earned an average rating of “Buy” from the fifteen analysts that are currently covering the firm, Marketbeat.com reports. Fifteen research analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $152.67.

A number of equities research analysts have recently weighed in on NTRA shares. Robert W. Baird boosted their price target on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Piper Sandler upped their price target on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, November 18th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. TD Cowen raised their target price on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, JPMorgan Chase & Co. boosted their price target on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, December 13th.

Natera Stock Up 1.5 %

Shares of Natera stock opened at $160.60 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The stock has a market cap of $21.20 billion, a price-to-earnings ratio of -91.25 and a beta of 1.63. The firm’s 50-day moving average is $154.07 and its two-hundred day moving average is $129.44. Natera has a 1 year low of $58.53 and a 1 year high of $175.63.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter last year, the firm earned ($0.95) EPS. The business’s revenue for the quarter was up 63.9% on a year-over-year basis. As a group, research analysts expect that Natera will post -1.61 earnings per share for the current fiscal year.

Insider Activity

In other Natera news, CEO Steven Leonard Chapman sold 1,709 shares of the stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $120.76, for a total transaction of $206,378.84. Following the completion of the transaction, the chief executive officer now owns 194,615 shares of the company’s stock, valued at $23,501,707.40. This trade represents a 0.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Solomon Moshkevich sold 256 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total transaction of $30,737.92. Following the completion of the transaction, the insider now owns 111,891 shares in the company, valued at approximately $13,434,752.37. This represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 127,932 shares of company stock valued at $20,635,430 in the last 90 days. Company insiders own 7.60% of the company’s stock.

Institutional Trading of Natera

Several hedge funds have recently made changes to their positions in NTRA. Itau Unibanco Holding S.A. purchased a new position in Natera in the second quarter valued at $28,000. Quarry LP raised its position in Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares in the last quarter. Covestor Ltd boosted its stake in shares of Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares during the period. GAMMA Investing LLC grew its position in shares of Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after buying an additional 106 shares in the last quarter. Finally, True Wealth Design LLC purchased a new stake in shares of Natera during the third quarter worth approximately $57,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.